Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
folfox4 + recombinant human endostatin
- Development stage
- Unknown
- Lead developer
- Simcere Pharmaceutical Group
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
FOLFOX4 + recombinant human endostatin is a combination regimen used primarily in oncology clinical research, especially for advanced or metastatic colorectal cancer and other solid tumors. FOLFOX4 consists of three chemotherapeutic agents—oxaliplatin, fluorouracil (5-FU), and folinic acid (leucovorin)—administered in a specific schedule over two days every two weeks. These drugs act synergistically to inhibit DNA synthesis and cell division in rapidly proliferating cancer cells[2][3][6]. Recombinant human endostatin is an anti-angiogenic biologic agent that inhibits the formation of new blood vessels by targeting endothelial cell proliferation, thereby starving tumors of their blood supply. The combination aims to enhance antitumor efficacy by attacking both tumor cells directly (via chemotherapy) and indirectly (by inhibiting angiogenesis with endostatin).
02
Targets
HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))ITGA5:ITGB1 (Integrin α5β1)αVβ3 (Integrin αVβ3)TS (Thymidylate synthase)VEGFR2 (Vascular endothelial growth factor receptor 2)Pt-DNA adduct (DNA-oxaliplatin adduct)DHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on folfox4 + recombinant human endostatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on folfox4 + recombinant human endostatin.